Slide decks focusing on key results and expert analysis from FOURIER, ODYSSEY OUTCOMES and ODYSSEY trials – all landmark trials in PCSK9 inhibition.
16-18 November, Philadelphia, USA
ORION-9: durable and potent LDL-C lowering in HeFH patients on twice yearly dosing
ORION-10: effective LDL-C lowering in patients with ASCVD with twice yearly dosing
FOURIER: effects of evolocumab on cognition and following MI